Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI

Recruiting now

Conditions studied: MIBC, mpMRI, NAC

In brief

Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.

Key facts

Study ID

NCT07202845

Run by

Assiut University

People needed

39

Starts

2025-08-29

Expected to finish

2026-06-01

Last updated by the study team

2025-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements.
• Planned to receive cisplatin-based NAC followed by radical cystectomy.
• Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).

You may not qualify if…

• Patients who have received pelvic radiotherapy.
• Severe renal impairment
• Previous open or laparoscopic pelvic surgery.
• Presence of distant metastases at diagnosis.
• Patients with contraindications to MRI.
• Ineligibility to cisplatin

Where it is running

• Amr E. Darwish — Asyut, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.